A metabolic perspective on nitric oxide function in melanoma

John Jimenez1, Parul Dubey2, Bethany Carter3

  • 1Department of Cutaneous Oncology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA; Department of Oncologic Sciences, University of South Florida Morsani School of Medicine, Tampa, FL 33612, USA.

Insights

Nitric oxide (NO) impacts melanoma by either suppressing or promoting tumor growth, depending on its concentration and cellular origin. Understanding NO-linked metabolites is key to exploring therapeutic strategies for melanoma metabolic dysfunction.

Area of Science:

  • Oncology
  • Biochemistry
  • Melanoma Research

Background:

  • Nitric oxide (NO) produced by nitric oxide synthase (NOS) has a dual role in melanoma progression.
  • The effect of NO is dependent on intracellular concentration and cell type.
  • NO significantly influences cellular metabolism, impacting signaling and stress responses in melanoma.

Purpose of the Study:

  • To review known metabolites linked to NO production in melanoma.
  • To elucidate the synthesis and biochemical roles of these metabolites.
  • To understand how these metabolites alter the melanoma tumor microenvironment and reinforce NO's dual role.

Main Methods:

  • Literature review of studies on nitric oxide, nitric oxide synthase, and melanoma metabolism.
  • Analysis of biochemical pathways involving NO-related metabolites.
  • Examination of the impact of these metabolites on the melanoma tumor microenvironment.

Main Results:

  • Identified key metabolites associated with NO production in melanoma.
  • Detailed their synthesis and involvement in critical metabolic pathways.
  • Demonstrated how these metabolites contribute to the dichotomous effects of NO in melanoma.

Conclusions:

  • Nitric oxide's dual role in melanoma is reinforced by its influence on metabolic pathways and associated metabolites.
  • Investigating NO-linked metabolites offers potential therapeutic intervention strategies for melanoma.
  • Understanding metabolic dysfunction driven by NO is crucial for targeted melanoma treatments.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.0K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
13.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.5K